Specificity of vascular endothelial growth factor treatment for radiation necrosis.
other
Where this comes from
- Record sourced from PubMed, PMID 26376163.
- Also identified by DOI 10.1016/j.radonc.2015.09.004 and PMC identifier 4854530.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
Medical subject headings
- Brain
- Radiation Injuries, Experimental
- Vascular Endothelial Growth Factor A